Zhang Bocheng, Tan Haolei, Kuang Jingyu, Zhou Bo, Liang Shixuan, Pang Xiao, Ouyang Yu, Zhang Zhang, Long Ying, Zhang Hailin
Hunan provincial clinical research centre for oncoplastic surgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, P. R. China.
Department of Head and Neck surgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, P. R. China.
Mol Cancer. 2025 Nov 10;24(1):284. doi: 10.1186/s12943-025-02487-4.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a highly aggressive malignant tumor. Traditional therapeutic approaches have limited efficacy in locally advanced HNSCC patients, and neoadjuvant immunotherapy has emerged as a new hope. However, the current outcomes of neoadjuvant immunotherapy for HNSCC are not yet optimal and urgently need improvement. This article comprehensively reviews the clinical research progress of neoadjuvant immunotherapy in the field of HNSCC treatment. By integrating perspectives from the regulatory mechanisms of the immune microenvironment, we propose future research directions for enhancing the efficacy of neoadjuvant immunotherapy for HNSCC patients.
头颈部鳞状细胞癌（HNSCC）是一种侵袭性很强的恶性肿瘤。传统治疗方法对局部晚期HNSCC患者的疗效有限，新辅助免疫治疗已成为新的希望。然而，目前HNSCC新辅助免疫治疗的效果尚不理想，迫切需要改进。本文全面综述了HNSCC治疗领域新辅助免疫治疗的临床研究进展。通过整合免疫微环境调控机制的观点，我们提出了提高HNSCC患者新辅助免疫治疗疗效的未来研究方向。
